| Tbio | RNA-binding protein 14 |
Isoform 1 may function as a nuclear receptor coactivator, enhancing transcription through other coactivators such as NCOA6 and CITED1. Isoform 2, functions as a transcriptional repressor, modulating transcriptional activities of coactivators including isoform 1, NCOA6 and CITED1 (PubMed:11443112). Regulates centriole biogenesis by suppressing the formation of aberrant centriolar protein complexes in the cytoplasm and thus preserving mitotic spindle integrity. Prevents the formation of the STIL-CENPJ complex (which can induce the formation of aberrant centriolar protein complexes) by interfering with the interaction of STIL with CENPJ (PubMed:25385835). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728).
This gene encodes a ribonucleoprotein that functions as a general nuclear coactivator, and an RNA splicing modulator. This protein contains two RNA recognition motifs (RRM) at the N-terminus, and multiple hexapeptide repeat domain at the C-terminus that interacts with thyroid hormone receptor-binding protein (TRBP), and is required for transcription activation. Alternatively spliced transcript variants encoding different isoforms (with opposing effects on transcription) have been described for this gene. [provided by RefSeq, Oct 2011]
This gene encodes a ribonucleoprotein that functions as a general nuclear coactivator, and an RNA splicing modulator. This protein contains two RNA recognition motifs (RRM) at the N-terminus, and multiple hexapeptide repeat domain at the C-terminus that interacts with thyroid hormone receptor-binding protein (TRBP), and is required for transcription activation. Alternatively spliced transcript variants encoding different isoforms (with opposing effects on transcription) have been described for this gene. [provided by RefSeq, Oct 2011]
Comments
| Disease | Target Count | P-value |
|---|---|---|
| medulloblastoma, large-cell | 6241 | 5.7e-05 |
| psoriasis | 6694 | 1.0e-04 |
| tuberculosis and treatment for 3 months | 179 | 3.5e-04 |
| COPD | 118 | 1.2e-03 |
| atypical teratoid / rhabdoid tumor | 5112 | 2.5e-03 |
| osteosarcoma | 7950 | 2.7e-03 |
| ependymoma | 4679 | 5.2e-03 |
| oligodendroglioma | 2850 | 5.2e-03 |
| glioblastoma | 5792 | 5.7e-03 |
| group 4 medulloblastoma | 1855 | 8.1e-03 |
| astrocytic glioma | 2597 | 1.3e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Farber lipogranulomatosis | 9 | 3.331 | 1.7 |
| Kennedy's disease | 11 | 3.206 | 1.6 |
| Disease | log2 FC | p |
|---|---|---|
| astrocytic glioma | 1.100 | 1.3e-02 |
| atypical teratoid / rhabdoid tumor | 1.300 | 2.5e-03 |
| COPD | -1.300 | 1.2e-03 |
| ependymoma | 1.800 | 5.2e-03 |
| glioblastoma | 1.100 | 5.7e-03 |
| group 4 medulloblastoma | 1.300 | 8.1e-03 |
| medulloblastoma, large-cell | 1.900 | 5.7e-05 |
| oligodendroglioma | 1.600 | 5.2e-03 |
| osteosarcoma | 1.167 | 2.7e-03 |
| psoriasis | -2.000 | 1.0e-04 |
| tuberculosis and treatment for 3 months | -1.200 | 3.5e-04 |
MKIFVGNVDGADTTPEELAALFAPYGTVMSCAVMKQFAFVHMRENAGALRAIEALHGHELRPGRALVVEM 1 - 70 SRPRPLNTWKIFVGNVSAACTSQELRSLFERRGRVIECDVVKDYAFVHMEKEADAKAAIAQLNGKEVKGK 71 - 140 RINVELSTKGQKKGPGLAVQSGDKTKKPGAGDTAFPGTGGFSATFDYQQAFGNSTGGFDGQARQPTPPFF 141 - 210 GRDRSPLRRSPPRASYVAPLTAQPATYRAQPSVSLGAAYRAQPSASLGVGYRTQPMTAQAASYRAQPSVS 211 - 280 LGAPYRGQLASPSSQSAAASSLGPYGGAQPSASALSSYGGQAAAASSLNSYGAQGSSLASYGNQPSSYGA 281 - 350 QAASSYGVRAAASSYNTQGAASSLGSYGAQAASYGAQSAASSLAYGAQAASYNAQPSASYNAQSAPYAAQ 351 - 420 QAASYSSQPAAYVAQPATAAAYASQPAAYAAQATTPMAGSYGAQPVVQTQLNSYGAQASMGLSGSYGAQS 421 - 490 AAAATGSYGAAAAYGAQPSATLAAPYRTQSSASLAASYAAQQHPQAAASYRGQPGNAYDGAGQPSAAYLS 491 - 560 MSQGAVANANSTPPPYERTRLSPPRASYDDPYKKAVAMSKRYGSDRRLAELSDYRRLSESQLSFRRSPTK 561 - 630 SSLDYRRLPDAHSDYARYSGSYNDYLRAAQMHSGYQRRM 631 - 669 //
